AstraZeneca's Bydureon BCise Receives EU approval Once-Weekly Prefilled Syringe for Type2 Diabetes
Shots:
- This approval is based on data from DURATION-NEO-1 enrolling 375 patients for duration of 28 wks and DURATION-NEO-2- showing its safety and efficacy
- The study involves evaluation of Bydureon BCise IV qw- showing (reduction in HbA1c with 1.4% vs. 1.0% for Byetta BID IV for 28 wks.); (reduction in mean wt. 1.5 Kg vs. 1.9 Kg (baseline-97 Kg) in combination with oral antidiabetic medicines)
- This new Bydureon BCise 2mg formulation qw has also received FDA approval in Oct 2017
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com